Ticker brief · 2026-07-03
AMGN AMGEN INC
AMGN debate splits between regulatory pressure and defensive setup
Consumer, Non-cyclical · Biotechnology
Lean: mixedlast close
$374.15
1 day
+3.5%
14 days
+10.8%
mkt cap
$201.9B
signals 14d
46
authors 14d
26
AMGN sentiment is nearly flat, with credible bears focused on Tavneos regulatory fallout and new Tepezza competition while bulls lean on defensive healthcare rotation and technical strength. The late-week shift was negative: Roche Phase 3 divarasib data added oncology-competition pressure after earlier Tavneos and Lumvoa headlines. The trade structure looks like a range-bound large-cap healthcare debate unless $360 breakout follow-through offsets product-specific regulatory risk.
BULL CAMP
Bulls argue AMGN benefits from healthcare rotation, a constructive technical setup near $350-$360, and BMO's $400 Outperform stance. The bullish case is more chart and allocation-led than product-led.
Key voices@TheProfInvestorMEDIUM-HIGHC+0.27@PersimmonTIMEDIUM-HIGHA-0.32@TradesWithTomMEDIUMC+0.90@SevenParrMEDIUMC-1.66@EmmanuelInvestLOW-MEDIUMC-1.12
“AMGN daily breakout looks constructive if it can break and hold 360”— @TradesWithTom · tweet ↗
BEAR / SKEPTIC
Bears center on AMGN's product franchise risk: Tavneos faces revocation or withdrawal pressure, Lumvoa creates Tepezza competition, and obesity/oncology assets look weaker than rivals. The bear camp has more company-specific evidence than the bull camp.
Key voices@schaeffersHIGHC-3.72@BioStocksMEDIUM-HIGHC-0.39@fwpharmaMEDIUM-HIGHB+0.22@FiercePharmaMEDIUM-HIGHB+1.39@bioinvestor24MEDIUM-HIGHA+1.35
“NEJM retraction and FDA withdrawal proposal increase Tavneos regulatory risk”— @schaeffers · tweet ↗
Hypotheses9direction · basis · magnitude · supporters — NEW = first seen this week
▼Tavneos faces material regulatory and reputational risk after EMA, CHMP, NEJM and FDA actions questioned study data integrity.
▼Viridian Lumvoa approval introduces direct thyroid eye disease competition that could pressure AMGN's Tepezza franchise.
▼AMGN's obesity assets look less competitive than peers, limiting re-rating potential in the GLP-1 obesity theme.
@bioinvestor24MEDIUM-HIGHA+1.353s · insight@PersimmonTIMEDIUM-HIGHA-0.321s · insight
▼Roche divarasib Phase 3 outperformance versus Amgen and BMS rivals signals oncology competitive pressure.
@EmmanuelInvestLOW-MEDIUMC-1.121s@bioinvestor24MEDIUM-HIGHA+1.351s · insight
▲Defensive healthcare rotation should favor AMGN and large-cap healthcare during Nasdaq weakness and 2026-2027 allocation shifts.
@DonDrapperrMEDIUMB+0.401s@TheProfInvestorMEDIUM-HIGHC+0.271s@dannycheng2022MEDIUMC-1.681s@AsafNaamaniLOW-MEDIUMC-2.111s
▲AMGN's chart is constructive, with bullish engulfing and breakout setups requiring follow-through above 350-360.
@SevenParrMEDIUMC-1.662s@TradesWithTomMEDIUMC+0.901s@foy_cerenseverLOW-MEDIUMC-0.011s@RachelDashCSMEDIUM-HIGHC-0.271s@AsafNaamaniLOW-MEDIUMC-2.111s
▲AMGN remains attractive within AMGN/XBI positioning despite product concerns, supported by constructive sentiment and chart interest.
@PersimmonTIMEDIUM-HIGHA-0.321s · insight@OptionsHawkHIGHB+1.331s · insight
▲BMO's reiterated Outperform rating and $400 PT support a bullish AMGN sell-side anchor.
@EmmanuelInvestLOW-MEDIUMC-1.121s
◆AMGN-adjacent chatter contains scattered low-signal peer and basket mentions rather than a clean single-stock thesis.
Direct calls1authors taking explicit directional positions
@bioinvestor24MEDIUM-HIGHA+1.35
Probably time to consider a long-term PFE position
Sellside activity6
Oppenheimer initiate PT 17Initiated EPRX at Outperform with $17 target
Citizens reiterate PT 35Reiterated VRDN Market Outperform $35 after FDA approval of Lumvoa
UBS reiterate PT 50Reiterated VRDN Buy $50 after Lumvoa approval with TAM and launch expectations
William Blair reiterateReiterated bullish VRDN view after Lumvoa approval
Wedbush pt_raise PT 43 (from 32)Raised VRDN PT to $43 from $32 while reiterating bullish view
BMO reiterate PT 400Reiterated AMGN Outperform with $400 PT
News / data points5discrete events + data quoted by authors
@BioStocksMEDIUM-HIGHC-0.39
EMA recommended revoking Tavneos marketing authorization
@schaeffersHIGHC-3.72
NEJM retracted Tavneos trial after FDA findings and proposed U.S. withdrawal
@FiercePharmaMEDIUM-HIGHB+1.39
Viridian's Lumvoa FDA approval creates new competition for Tepezza
@EmmanuelInvestLOW-MEDIUMC-1.12
Roche divarasib outperformed Amgen and BMS rival therapies in Phase 3
@TradesWithTomMEDIUMC+0.90
AMGN daily breakout needs to break and hold 360
Position disclosures1skin in the game
@TravisBiziorekMEDIUMC+0.45
Reports existing positions and new positions, plus BIIB target hit
Desk readconvergence assessment
The view is not converged: company-specific bears have the cleaner evidence trail, while bulls mostly cite sector rotation, charts, and a single BMO $400 PT. Credibility is mixed on both sides, but several bear anchors are medium-high or high credibility despite schaeffers having a very cold trader_score_20 of -3.72. A sustained break and hold above 360 would challenge the bear skew; additional Tavneos withdrawal steps or Tepezza share-loss evidence would strengthen it.
Sentiment — last 14 days
daily mean sentiment, 2026-06-23 → 2026-07-03 · now +0.40 (−1 bearish … +1 bullish)
Who spoke26
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | +1.35 | 8 | -0.11 |
| @Quantumup1 | C | -1.95 | 4 | +0.00 |
| @PersimmonTI | A | -0.32 | 3 | +0.22 |
| @Jaymin_Alpha | B | -0.41 | 2 | +0.23 |
| @BioStocks | C | -0.39 | 2 | -0.50 |
| @fwpharma | B | +0.22 | 2 | -0.30 |
| @SevenParr | C | -1.66 | 2 | +0.40 |
| @AsafNaamani | C | -2.11 | 2 | +0.40 |
| @schaeffers | C | -3.72 | 2 | -0.58 |
| @FiercePharma | B | +1.39 | 2 | -0.20 |
| @EmmanuelInvest | C | -1.12 | 2 | +0.10 |
| @TheETFTracker | C | -0.29 | 1 | +0.00 |
| @PrismMarketView | C | · | 1 | +0.15 |
| @TradesWithTom | C | +0.90 | 1 | +0.45 |
| @DonDrapperr | B | +0.40 | 1 | +0.35 |
| @TravisBiziorek | C | +0.45 | 1 | +0.20 |
| @TheProfInvestor | C | +0.27 | 1 | +0.55 |
| @FromValue | B | -0.27 | 1 | +0.00 |
| @dannycheng2022 | C | -1.68 | 1 | +0.70 |
| @harmongreg | B | +0.03 | 1 | +0.00 |
| @financespotnews | C | -0.87 | 1 | -0.05 |
| @RachelDashCS | C | -0.27 | 1 | +0.45 |
| @foy_cerensever | C | -0.01 | 1 | +0.35 |
| @HedgeFundTips | B | -0.75 | 1 | +0.00 |
| @Barchart | C | · | 1 | +0.00 |
Recent signals30of 46 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-03 | @PersimmonTI | +0.45 | Calls AMGN/XBI a very attractive position, with chart link. | — | tweet ↗ |
| 2026-07-03 | @AsafNaamani | +0.35 | Healthcare recap lists breakouts, bases and retests across sector names. | — | tweet ↗ |
| 2026-07-02 | @OptionsHawk | +0.20 | Mentions prior solid action in AMGN, MA and RDDT. | — | tweet ↗ |
| 2026-07-01 | @EmmanuelInvest | -0.20 | Roche divarasib outperformed Amgen and BMS rival therapies in Phase 3 trial. | +3.5% | tweet ↗ |
| 2026-07-01 | @Barchart | +0.00 | QNT gained 35% from IPO price; mentions backing by NVDA, JPM, AMGN and 2X ETF exposure. | +3.5% | tweet ↗ |
| 2026-07-01 | @EmmanuelInvest | +0.40 | BMO reiterates AMGN Outperform with $400 PT. | +3.5% | tweet ↗ |
| 2026-06-30 | @bioinvestor24 | +0.00 | Probably time to consider a long-term PFE position — Suggests a long-term Pfizer position amid potential shakeup or large deal. | +3.3% | tweet ↗ |
| 2026-06-30 | @bioinvestor24 | -0.25 | Says obesity competition is inferior and Lilly faces weak rivals. | +3.3% | tweet ↗ |
| 2026-06-30 | @bioinvestor24 | -0.15 | Says ABBV has strong commercial setup for obesity while others' trials/deals create caution. | +3.3% | tweet ↗ |
| 2026-06-30 | @HedgeFundTips | +0.00 | Dow 30 earnings estimates and revisions chart is shared. | +3.3% | tweet ↗ |
| 2026-06-30 | @FiercePharma | -0.25 | Journal retraction complicates Amgen defense effort. | +3.3% | tweet ↗ |
| 2026-06-30 | @FiercePharma | -0.15 | Viridian secured FDA approval for Lumvoa, creating competition for Amgen Tepezza. | +3.3% | tweet ↗ |
| 2026-06-30 | @foy_cerensever | +0.35 | AMGN has run well and can be followed with 350 stop. | +3.3% | tweet ↗ |
| 2026-06-29 | @schaeffers | -0.60 | Says FDA-alleged data changes create regulatory risk and Tavneos faces market withdrawal. | +3.8% | tweet ↗ |
| 2026-06-29 | @schaeffers | -0.55 | NEJM retracted Tavneos trial after FDA findings; FDA proposed withdrawal from U.S. market. | +3.8% | tweet ↗ |
| 2026-06-29 | @RachelDashCS | +0.45 | Lists bullish inverse H&S and breakout chart setups with upside levels for several tickers. | +3.8% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | William Blair and Wedbush reiterate bullish VRDN views; Wedbush raises PT to $43 from $32. | +3.8% | tweet ↗ |
| 2026-06-29 | @financespotnews | -0.05 | FDA approved Viridian drug for thyroid eye disease, creating commercial milestone. | +3.8% | tweet ↗ |
| 2026-06-29 | @fwpharma | -0.10 | Viridian thyroid eye disease drug won FDA approval, competing with Amgen Tepezza. | +3.8% | tweet ↗ |
| 2026-06-29 | @AsafNaamani | +0.45 | Shares bullish healthcare setups and says XLV is approaching key breakout. | +3.8% | tweet ↗ |
| 2026-06-29 | @harmongreg | +0.00 | Mentions trade ideas for Amgen but no standalone trade mechanics or stance. | +3.8% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | UBS reiterates VRDN Buy $50 after Lumvoa approval and outlines TAM and launch expectations. | +3.8% | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | Citizens reiterates VRDN Market Outperform $35 after FDA approval of Lumvoa. | +3.8% | tweet ↗ |
| 2026-06-28 | @bioinvestor24 | -0.45 | Says AMGN obesity and oncology assets feel inadequate while peers are more competitive. | +4.4% | tweet ↗ |
| 2026-06-28 | @dannycheng2022 | +0.70 | Health sector setups are bullish with uptrends, strong candles, and whale accumulation. | +4.4% | tweet ↗ |
| 2026-06-28 | @FromValue | +0.00 | Reports Alphabet joining Dow and Verizon being replaced, followed by constituent list. | +4.4% | tweet ↗ |
| 2026-06-28 | @SevenParr | +0.25 | Compares AMGN weekly entry candle to UNP setup. | +4.4% | tweet ↗ |
| 2026-06-28 | @SevenParr | +0.55 | Says AMGN has great risk/reward and odds from bullish engulfing pattern. | +4.4% | tweet ↗ |
| 2026-06-28 | @TheProfInvestor | +0.55 | Detailed 2026-2027 rotation playbook bullish healthcare first, then tech/financials. | +4.4% | tweet ↗ |
| 2026-06-27 | @bioinvestor24 | +0.10 | Detailed thesis on VKTX obesity asset, CEO execution issues, and BP acquisition hesitation. | +4.4% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.